Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?
The Scientist
Most Recent
The FDA approves an antibody-drug conjugate that effectively treats a certain type of advanced breast cancer with fewer side effects than previous drugs.
Researchers have created a molecule that helps nanoparticles evade immune attack and could improve drug delivery.
Three Silicon Valley entrepreneurs are offering $3 million to scientists demonstrating excellence in biology and medical research.
Disruptions in the interaction between nuclear and mitochondrial DNA can lead to deficiencies in the mitochondrial energy-generating process, affecting fitness.
The first human trial of a treatment using induced pluripotent stem cells has received conditional approval from an institutional review board in Japan.
A retinal prosthesis, already available in Europe, can restore partial sight to people with a genetic disorder that causes blindness.
Protein aggregates in the brains of some people with dementia or motor neuron disease have a surprising origin.
One of the most advanced tuberculosis vaccines has failed to protect infants from getting the disease in a clinical trial, but it may be effective in adults.
A company offering experimental stem-cell treatments will carry out its procedures in Mexico after the FDA warned that it would need approval to operate in the U.S.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
